Honasa Consumer, the parent company of popular personal care brand Mamaearth, has approved the acquisition of a majority stake in nutraceuticals company Fluence Pharma for ₹135 crore. This strategic move marks Honasa’s foray into the burgeoning nutrition and supplements sector, a market that has been gaining momentum in India due to increasing consumer awareness of health and wellness products.
### The Acquisition and Honasa’s Expansion Plans
Honasa Consumer will acquire a 58% stake in Fluence Pharma from its current shareholders in a transaction expected to be completed within eight weeks. The company also plans to purchase the remaining 42% equity stake over the next 5-7 years through secondary transactions. Founded in 2012, Fluence Pharma specializes in skin and hair health supplements and has a robust network of over 3,000 dermatologists and trichologists.
To support its new venture, Honasa has announced the creation of a new subsidiary, Honasa Health, which will focus on building a direct-to-consumer nutraceuticals business. Honasa Health will integrate Fluence Pharma’s patented Cyclical Nutrition Therapy (CNT) with Honasa’s distribution and marketing strengths, allowing for a seamless entry into the nutrition space. The subsidiary will start with an initial paid-up capital of ₹1 lakh.
### Nutraceuticals: A Growing Market
Honasa’s entry into the nutraceuticals sector aligns with its “Honasa 3.0” strategy, which aims to diversify its portfolio and reduce reliance on its flagship brand, Mamaearth. The Indian nutraceuticals market is currently valued at approximately ₹16,000 crore and is expected to grow as consumers increasingly seek holistic solutions for health and beauty.
The acquisition of Fluence Pharma allows Honasa to tap into the demand for “inside-out” beauty solutions, a trend gaining traction among health-conscious consumers. The company plans to leverage its existing distribution network, which it aims to expand from 1.2 lakh outlets to over 3 lakh outlets, to bolster its presence in this sector.
### Implications for India’s Startup Ecosystem
Honasa’s strategic acquisition highlights the growing interest in the nutraceuticals space among Indian startups and established companies alike. As consumer preferences shift towards health and wellness, more startups are likely to explore opportunities in this sector, leading to increased competition and innovation.
The move also reflects the broader trend of diversification among Indian startups, as companies seek to build multi-brand portfolios to mitigate risks and capture a larger market share. Honasa’s ambitious plan to double its revenue to over ₹5,500 crore by FY31 and improve EBITDA margins underscores the potential profitability of expanding into new verticals.
### What Lies Ahead
As Honasa integrates Fluence Pharma into its operations, industry observers will be keen to see how the company executes its multi-brand strategy and navigates the competitive nutraceuticals landscape. For founders and investors, this acquisition serves as a signal of the lucrative opportunities within India’s growing health and wellness market. The success of Honasa’s expansion could inspire similar strategic moves by other companies looking to capitalize on this trend. The market will be watching closely as Honasa rolls out new products and scales its operations in the coming years.
